{"disease":{"id":"acute-lymphoblastic-leukemia-in-relapse","name":"acute lymphoblastic leukemia in relapse"},"drugs":{"marketed":[{"drug_id":"tisagenlecleucel","indication_name":"B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06343090","title":"Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":353,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT06389305","title":"CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction","phase":"NA","overall_status":"RECRUITING","enrollment_count":213,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT04224571","title":"CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04603872","title":"CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT03751072","title":"Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)","phase":"","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Group for Research in Adult Acute Lymphoblastic Leukemia","has_results":false},{"nct_id":"NCT04340154","title":"Study of Sequential CAR-T Cell Treating Leukemia Children","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":81,"lead_sponsor_name":"Beijing Boren Hospital","has_results":false},{"nct_id":"NCT06316427","title":"Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT06213636","title":"Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT04881240","title":"Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT05137860","title":"Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":56,"lead_sponsor_name":"Hospital General de Mexico","has_results":false},{"nct_id":"NCT06316856","title":"CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07070323","title":"A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT05809284","title":"Determining the Mechanisms of Loss of CAR T Cell Persistence","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06326008","title":"Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT04191187","title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT03957915","title":"Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT03185494","title":"Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05292664","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Andrew E. Place, MD","has_results":false},{"nct_id":"NCT05705570","title":"Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Nelson Hamerschlak","has_results":false},{"nct_id":"NCT05658640","title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Princess Maxima Center for Pediatric Oncology","has_results":false},{"nct_id":"NCT05745714","title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Princess Maxima Center for Pediatric Oncology","has_results":false},{"nct_id":"NCT06641024","title":"Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03573700","title":"Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT03389035","title":"Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","has_results":false},{"nct_id":"NCT05066958","title":"Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT07087847","title":"Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04888442","title":"Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT06287528","title":"A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT04340167","title":"Study of Anti-CD22 CAR-T Cells Treating Leukemia Children","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Beijing Boren Hospital","has_results":false},{"nct_id":"NCT03705507","title":"International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT03515200","title":"Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT05054257","title":"CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology and Blood Transfusion, Czech Republic","has_results":false},{"nct_id":"NCT02181478","title":"Intra-Osseous Co-Transplant of UCB and hMSC","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04049383","title":"CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT04325841","title":"Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Beijing Boren Hospital","has_results":false},{"nct_id":"NCT04844086","title":"RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Eden BioCell Ltd.","has_results":false},{"nct_id":"NCT05740449","title":"HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Princess Maxima Center for Pediatric Oncology","has_results":false}],"total":39},"guidelines":[],"source":"Drug Landscape verified database"}